Development of 18F-labeled PET probes for imaging cell proliferation

Current Topics in Medicinal Chemistry

Volumn 13, Issue 8, 2013, Pages 892-908

  Sai, Kiran Kumar Solingapuram ^a   Jones, Lynne A ^a   Mach, Robert H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cell proliferation; DNA synthesis; Positron emission tomography; Radiotracer; Sigma 2 receptors

Indexed keywords

3 ETHYL 2, 3 DIHYDRO 2 OXO 1 BENZIMIDAZOLECARBOXYLIC ACID 3ALPHA TROPANYLAMIDE; [18F] 2' FLUORO 5 METHYL 1 BETA D ARABINOFURANOSYLURACIL; [18F] FLUORO 3' DEOXY 3' L FLUOROTHYMIDINE; BENZAMIDE; CYCLINE; FLUORINE 18; FLUOROURACIL; GEFITINIB; KI 67 ANTIGEN; SIRAMESINE; THYMIDINE DERIVATIVE; THYMIDINE KINASE 1; THYMIDINE PHOSPHATE; TRACER; TRIAZOLE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CULTURE; CELL PROLIFERATION; HUMAN; LIPOPHILICITY; LUNG ADENOCARCINOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; RADIOCHEMISTRY; SOLID TUMOR;

CELL PROLIFERATION; FLUORINE RADIOISOTOPES; HUMANS; MOLECULAR PROBES; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 84878779793     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313080003     Document Type: Article

References (142)

1. Mankoff, D. A.; Link, J. M.; Linden, H. M.; Sundararajan, L.; Krohn, K. A. Tumor receptor imaging. J. Nucl. Med. 2008, 49, 149S-163S.
2. Hanahan, D.; Weinberg, R. A. The hallmarks of Cancer Cell. 2000, 100, 57-70.
3. Bading, J. R.; Shields, A. F. Imaging of cell proliferation: Status and Prospects. J. Nucl. Med. 2008, 49, 64S-80S.
4. Colozza, M.; Azambuja, E.; Cardoso, F.; Sotiriou, C.; Larsimont, D.; Piccart, M. J. Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Ann. Oncol. 2005, 16, 1723-1739.
5. Hall, E. J.; Giaccia, A. J. Radiobiology for the Radiologist. 6th ed.; Lippencott Williams and Wilkins Publishing: Philidelphia, PA, 2006; p 656.
6. Sherley, J. L.; Kelly, T. J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem. 1988, 263, 8350-8358.
7. Armstrong, J. S. Mitochondria: a target for cancer therapy. Br. J. Pharmacol. 2006, 147, 239-248.
8. Kauffman, M. G.; Kelly, T. J. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol. Cell. Biol. 1991, 11, 2538-2546.
9. Boothman, D. A.; Davis, T. W.; Sahijdak, W. M. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys. 1994, 30, 391-398.
10. Munch-Petersen, B.; Cloos, L.; Jensen, H. K.; Tyrsted, G. Human thymidine kinase 1. Regulation in normal and malignant cells. Adv. Enzyme. Regul. 1995, 35, 69-89.
11. Masunaga, S.; Ono, K. Significance of the response of quiescent cell populations within solid tumors in cancer therapy. J. Radiat. Res. (Tokyo). 2002, 43, 11-25.
12. Hellewell, S. B.; Bowen, W. D. A sigma-like binding site in rat pheochromocytoma (PC12) cells: Decreased affinity for (+)benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain. Res. 1990, 527, 244-253.
13. Hellewell, S. B.; Bruce, A.; Feinstein, G.; Orringer, J.; Williams, W.; Bowen, W. D. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: Characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. 1994, 268, 9-18.
14. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; De Costa, B.; Rice, K. C. Sigma receptors: Biology and function. Pharmacol. Rev. 1990, 42, 355-402.
15. Maurice, T.; Junien, J. L.; Privat, A. Dehydroepiandrosterone sulfate attenuates dizocilpine-induced learning impairment in mice via sigma 1-receptors. Behav. Brain. Res. 1997, 83, 159-164.
16. 3H]SKF-10,047 binding to sigma-1 receptors in the mouse forebrain. J. Neurosci. Res. 1996, 46, 734-743.
17. Romieu, P.; Martin-Fardon, R.; Bowen, W. D.; Maurice, T. Sigma1 receptor-related neuroactive steroids modulate cocaine-induced reward. J. Neurosci. 2003, 23, 3572-3576.
18. Fontanilla, D.; Johannessen, M.; Hajipour, A. R.; Cozzi, N. V.; Jackson, M. B.; Ruoho, A. E. The hallucinogen N,Ndimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009, 323, 934-937.
19. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.; Striessnig, J.; Kempner, E.; Glossmann, H. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl. Acad. Sci. U. S. A. 1996, 93, 8072-8077.
20. Seth, P.; Leibach, F. H.; Ganapathy, V. Cloning and structural analysis of the cDNA and the gene encoding the murine type 1 sigma receptor. Biochem. Biophys. Res. Commun. 1997, 241, 535-540.
21. Hayashi, T.; Su, T. P. Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export. J. Pharmacol. Exp. Ther. 2003, 306, 718-725.
22. Palmer, C. P.; Mahen, R.; Schnell, E.; Djamgoz, M. B.; Aydar, E. Sigma-1 receptors bind cholesterol and remodel lipid rafts in breast cancer cell lines. Cancer Res. 2007, 67, 11166-11175.
23. Tsai, S. Y.; Hayashi, T.; Mori, T.; Su, T. P. Sigma-1 receptor chaperones and diseases. Cent. Nerv. Syst. Agents. Med. Chem. 2009, 9, 184-189.
24. Alonso, G.; Phan, V.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; Maurice, T. Immunocytochemical localization of the sigma-1 receptor in the adult rat central nervous system. Neuroscience. 2000, 97, 155-170.
25. Xu, J.; Zeng, C.; Chu, W.; Pan, F.; Rothfuss, J. M.; Zhang, F.; Tu, Z.; Zhou, D.; Zeng, D.; Vangveravong, S.; Johnston, F.; Spitzer, D.; Chang, K. C.; Hotchkiss, R. S.; Hawkins, W. G.; Wheeler, K. T.; Mach, R. H. Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2011, 2, 380.
26. Zeng, C.; Vangveravong, S.; Jones, L. A.; Hyrc, K.; Chang, K. C.; Xu, J.; Rothfuss, J. M.; Goldberg, M. P.; Hotchkiss, R. S.; Mach, R. H. Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Mol. Imaging. 2011.
27. Zeng, C.; Vangveravong, S.; Xu, J.; Chang, K. C.; Hotchkiss, R. S.; Wheeler, K. T.; Shen, D.; Zhuang, Z. P.; Kung, H. F.; Mach, R. H. Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res. 2007, 67, 6708-6716.
28. Abate, C.; Hornick, J. R.; Spitzer, D.; Hawkins, W. G.; Niso, M.; Perrone, R.; Berardi, F. Fluorescent derivatives of sigma receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells. J. Med. Chem. 2011, 54, 5858-5867.
29. Haller, J. L.; Panyutin, I.; Chaudhry, A.; Zeng, C.; Mach, R. H.; Frank, J. A. Sigma-2 receptor as potential indicator of stem cell differentiation. Mol. Imaging. Biol. 2012, 14, 325-335.
30. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55, 408-413.
31. Wallen, C. A.; Higashikubo, R.; Dethlefsen, L. A. Murine mammary tumour cells in vitro. II. Recruitment of quiescent cells. Cell. Tissue. Kinet. 1984, 17, 79-89.
32. Wallen, C. A.; Higashikubo, R.; Dethlefsen, L. A. Murine mammary tumour cells in vitro. I. The development of a quiescent state. Cell. Tissue. Kinet. 1984, 17, 65-77.
33. Mach, R. H.; Smith, C. R.; al-Nabulsi, I.; Whirrett, B. R.; Childers, S. R.; Wheeler, K. T. Sigma-2 receptors as potential biomarkers of proliferation in breast Cancer Cancer Res. 1997, 57, 156-161.
34. Al-Nabulsi, I.; Mach, R. H.; Wang, L. M.; Wallen, C. A.; Keng, P. C.; Sten, K.; Childers, S. R.; Wheeler, K. T. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumour cells. Br. J. Cancer 1999, 81, 925-933.
35. Bem, W. T.; Thomas, G. E.; Mamone, J. Y.; Homan, S. M.; Levy, B. K.; Johnson, F. E.; Coscia, C. J. Overexpression of sigma receptors in nonneural human tumors. Cancer Res. 1991, 51, 6558-6562.
36. Wheeler, K. T.; Wang, L. M.; Wallen, C. A.; Childers, S. R.; Cline, J. M.; Keng, P. C.; Mach, R. H. Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br. J. Cancer 2000, 82, 1223-1232.
37. Gunn, R. N.; Yap, J. T.; Wells, P.; Osman, S.; Price, P.; Jones, T.; Cunningham, V. J. A general method to correct PET data for tissue metabolites using a dual-scan approach. J. Nucl. Med. 2000, 41, 706-711.
38. Shields, A. F.; Grierson, J. R.; Dohmen, B. M.; Machulla, H. J.; Stayanoff, J. C.; Lawhorn-Crews, J. M.; Obradovich, J. E.; Muzik, O.; Mangner, T. J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med. 1998, 4, 1334-1336.
39. Grierson, J. R.; Shields, A. F. Radiosynthesis of 3 -deoxy-3 - [18F]fluorothymidine: [18F]FLT for imaging of cellular proliferation in vivo. Nucl. Med. Biol. 2000, 27, 143-156.
40. 18F]FIAU, as potential PET agents for imaging cellular proliferation: synthesis of [18F]labelled FAU, FMAU, FBAU, FIAU. Nucl. Med. Biol. 2003, 30, 215-224.
41. 18F-FMAU and PET. J. Nucl. Med. 2005, 46, 292-296.
42. 18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation. Cancer Biother. Radiopharm. 2003, 18, 327-337.
43. Shields, A. F.; Grierson, J. R.; Kozawa, S. M.; Zheng, M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl. Med. Biol. 1996, 23, 17-22.
44. Ljungdahl-Ståhle, E.; Guzenda, E.; Böttiger, D.; Wahren, B.; Oberg, B.; Ståhle, L. Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action. Antimicrob. Agents. Chemother. 1992, 36, 2418-2422.
45. 18F]FLT) in pancreatic cancer cell lines. Eur. J. Nucl. Med. Mol. Imaging. 2002, 29, 1174-1181.
46. 18F-FLT and thymidine analogs: Promise and pitfalls. J. Nucl. Med. 2003, 44, 1432-1434.
47. 3H-FMAU in proliferating and nonproliferating human tumor cells. J. Nucl. Med. 2010, 51, 1464-1471.
48. Grierson, J. R.; Schwartz, J. L.; Muzi, M.; Jordan, R.; Krohn, K. A. Metabolism of 3 -deoxy-3 -[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl. Med. Biol. 2004, 31, 829-837.
49. 18F]FLT. Nucl. Med. Biol. 2002, 29, 263-273.
50. 18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34, 1406-1409.
51. 18F]FLT) and simple method for metabolite analysis in plasma. Radiochimica. Acta. 2006, 94, 447-451.
52. 18F]fluorothymidine using three precursors. Appl. Radiat. Isot. 2006, 64, 187-193.
53. 18F]-3-deoxy-3-fluorothymidine using a nosylate precursor in ionic liquid ([bmim][OTf]). J. Labelled. Compd. Radiopharm. 2003, 46, S122.
54. 18F]fluorothymidine. Nucl. Med. Biol. 2004, 31, 803-809.
55. 18F-fluorothymidine in patients with gliomas. J. Nucl. Med. 2006, 47, 1612-1621.
56. Muzi, M.; Vesselle, H.; Grierson, J. R.; Mankoff, D. A.; Schmidt, R. A.; Peterson, L.; Wells, J. M.; Krohn, K. A. Kinetic analysis of 3 -deoxy-3 -fluorothymidine PET studies: Validation studies in patients with lung Cancer J. Nucl. Med. 2005, 46, 274-282.
57. 18F-FDG. J. Nucl. Med. 2003, 44, 1426-1431.
58. 18F]fluorothymidine-Positron Emission Tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 2002, 62, 3331-3334.
59. 18F-FDG. J. Nucl. Med. 2005, 46, 945-952.
60. 18F]FLT) as a proliferation imaging tracer in humans. Clin. Cancer Res. 2002, 8, 3315-3323.
61. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung Cancer Eur. J. Nucl. Med. Mol. Imaging. 2007, 34, 1610-1616.
62. 18F-Fluorodeoxyglucose-positron emission tomography. Chest. 2006, 129, 393-401.
63. 18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Res. 2005, 65, 10104-10112.
64. 18F]3 -deoxy-3 - fluorothymidine PET for the diagnosis and grading of brain tumors. Eur. J. Nucl. Med. Mol. Imaging. 2005, 32, 653-659.
65. 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35, 2009-2017.
66. 18F-fluorothymidine kinetics of malignant brain tumors. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34, 1003-1011.
67. Ullrich, R.; Backes, H.; Li, H.; Kracht, L.; Miletic, H.; Kesper, K.; Neumaier, B.; Heiss, W.-D.; Wienhard, K.; Jacobs, A. H. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin. Cancer Res. 2008, 14, 2049-2055.
68. Schwartz, J. L.; Tamura, Y.; Jordan, R.; Grierson, J. R.; Krohn, K. A. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J. Nucl. Med. 2003, 44, 2027-2032.
69. 18F]fluoro-2-deoxy-Dglucose in positron emission tomography for colorectal Cancer Eur. J. Nucl. Med. Mol. Imaging. 2003, 30, 988-994.
70. Mach, R. H.; Dehdashti, F.; Wheeler, K. T. PET radiotracers for imaging the proliferative status of solid tumors. PET. Clinics. 2009, 4, 1-15.
71. 18F-FDG PET in esophageal Cancer J. Nucl. Med. 2005, 46, 400-404.
72. 18F]fluoroethyl)-thymidine. Nucl. Med. Biol. 2006, 33, 765-772.
73. Muzi, M.; Mankoff, D. A.; Grierson, J. R.; Wells, J. M.; Vesselle, H.; Krohn, K. A. Kinetic modeling of 3 -deoxy-3 -fluorothymidine in somatic tumors: Mathematical studies. J. Nucl. Med. 2005, 46, 371-380.
74. Smith, M. B.; March, J. March's Advanced Organic Chemistry - Reactions, Mechanisms, and Structure (6th Edition). John Wiley & Sons: 2007; Vol. 6.
75. Wang, J.; Eriksson, S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2'-deoxy-2'-fluoro-1-beta-Darabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob. Agents. Chemother. 1996, 40, 1555-1557.
76. 18F] labeled arabinofuranosyl nucleosides. Nucl. Med. Biol. 2012, (in press).
77. 18F]-FMAU). Nucl. Med. Biol. 2012, 39, 1019-1025.
78. 18F]FCAU, [18F]FBAU and [18F]FIAU) using a multistep one-pot strategy. Nucl. Med. Biol. 2011, 38, 659-666.
79. 18F]fluoro-1--D-arabinofuranosyluracil and its 5- substituted nucleosides. J. Labelled. Compd. Radiopharm. 2003, 46, 285-289.
80. 18F]-FMAU) using a one reactor radiosynthesis module. Nucl. Med. Biol. 2011, 38, 201-206.
81. 18F]-FMAU using a novel dual reactor radiosynthesis module. J. Labelled. Compd. Radiopharm. 2009, 52, 553-558.
82. 18F]FMAU and positron emission tomography in patients with Cancer Eur. J. Nucl. Med. Mol. Imaging. 2005, 32, 15-22.
83. Gray, K. R.; Contractor, K. B.; Kenny, L. M.; Al-Nahhas, A.; Shousha, S.; Stebbing, J.; Wasan, H. S.; Coombes, R. C.; Aboagye, E. O.; Turkheimer, F. E.; Rosso, L. Kinetic filtering of [18F]Fluorothymidine in positron emission tomography studies. Phys. Med. Biol. 2010, 55, 695.
84. 18F- fluoro--D- arabinofuranosyl)thymine and PET. J. Nucl. Med. 2007, 48, 1436-1441.
85. 18F]3 -deoxy-3 -fluorothymidine metabolism and retention. Eur. J. Nucl. Med. Mol. Imaging. 2005, 32, 1269-1275.
86. Bading, J. R.; Shahinian, A. H.; Vail, A.; Bathija, P.; Koszalka, G. W.; Koda, R. T.; Alauddin, M. M.; Fissekis, J. D.; Conti, P. S. Pharmacokinetics of the thymidine analog 2 -fluoro-5-methyl-1-- D-arabinofuranosyluracil (FMAU) in tumor-bearing rats. Nucl. Med. Biol. 2004, 31, 407-418.
87. Nottebrock, H.; Then, R. Thymidine concentrations in serum and urine of different animal species and man. Biochem. Pharm. 1977, 26, 2175-2179.
88. Munch-Petersen, B.; Cloos, L.; Tyrsted, G.; Eriksson, S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J. Biol. Chem. 1991, 266, 9032-9038.
89. 18F-FLT)-a pilot study. Eur. J. Surg. Oncol. 2006, 32, 39-43.
90. 124I]iodo-2 -deoxyuridine for functional PET imaging of cell proliferation. Nucl. Med. Biol. 1998, 25, 359-365.
91. Tjuvajev, J. G.; Macapinlac, H. A.; Daghighian, F.; Scott, A. M.; Ginos, J. Z.; Finn, R. D.; Kothari, P.; Desai, R.; Zhang, J.; Beattie, B.; Graham, M.; Larson, S. M.; Blasberg, R. G. Imaging of brain tumor proliferative activity with Iodine-131-iododeoxyuridine. J. Nucl. Med. 1994, 35, 1407-1417.
92. Bergström, M.; Lu, L.; Fasth, K.-J.; Wu, F.; Bergström-Pettermann, E.; Tolmachev, V.; Hedberg, E.; Cheng, A.; Långstrom, B. In vitro and animal validation of Bromine-76-bromodeoxyuridine as a proliferation marker. J. Nucl. Med. 1998, 39, 1273-1279.
93. Lu, L.; Bergström, M.; Fasth, K.-J.; Wu, F.; Eriksson, B.; Långström, B. Elimination of nonspecific radioactivity from [76Br]bromide in PET study with [76Br]bromodeoxyuridine. Nucl. Med. Biol. 1999, 26, 795-802.
94. 76Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model. Eur. J. Nucl. Med. Mol. Imaging. 2002, 29, 19-27.
95. Lu, L.; Bergström, M.; Fasth, K.-J.; Långström, B. Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. J. Nucl. Med. 2000, 41, 1746-1752.
96. 18F-fluoro-1- -D-arabinofuranosyl)-5-bromouracil: PET imaging studies in dogs. J. Nucl. Med. 2005, 46, 1916-1922.
97. Kao, C.-H. K.; Waki, A.; Sassaman, M. B.; Jagoda, E. M.; Szajek, L. P.; Ravasi, L.; Shimoji, K.; Eckelman, W. C. Evaluation of [76Br]FBAU 3,5 -dibenzoate as a lipophilic prodrug for brain imaging. Nucl. Med. Biol. 2002, 29, 527-535.
98. 18F]FBAU. Nucl. Med. Biol. 2008, 35, 635-643.
99. Toyohara, J.; Hayashi, A.; Gogami, A.; Hamada, M.; Hamashima, Y.; Katoh, T.; Node, M.; Fujibayashi, Y. Alkyl-fluorinated thymidine derivatives for imaging cell proliferation: I. The in vitro evaluation of some alkyl-fluorinated thymidine derivatives. Nucl. Med. Biol. 2006, 33, 751-764.
100. Byun, Y.; Yan, J.; Al-Madhoun, A. S.; Johnsamuel, J.; Yang, W.; Barth, R. F.; Eriksson, S.; Tjarks, W. Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for Boron Neutron Capture Therapy. J. Med. Chem. 2005, 48, 1188-1198.
101. Desbouis, D.; Struthers, H.; Spiwok, V.; Küster, T.; Schibli, R. Synthesis, in vitro, and in silico evaluation of organometallic Technetium and Rhenium thymidine complexes with retained substrate activity toward human Thymidine Kinase Type 1. J. Med. Chem. 2008, 51, 6689-6698.
102. Byun, Y.; Yan, J.; Al-Madhoun, A. S.; Johnsamuel, J.; Yang, W.; Barth, R. F.; Eriksson, S.; Tjarks, W. The synthesis and biochemical evaluation of thymidine analogues substituted with nido carborane at the N-3 position. Appl. Radiat. Isot. 2004, 61, 1125-1130.
103. 18F]fluoropropyl thymidine. Nucl. Med. Biol. 2008, 35, 697-705.
104. Smith, G.; Sala, R.; Carroll, L.; Behan, K.; Glaser, M.; Robins, E.; Nguyen, Q.-D.; Aboagye, E. O. Synthesis and evaluation of nucleoside radiotracers for imaging proliferation. Nucl. Med. Biol. 2012, 39, 652-665.
105. Eary, J. F.; Mankoff, D. A.; Spence, A. M.; Berger, M. S.; Olshen, A.; Link, J. M.; O'Sullivan, F.; Krohn, K. A. 2-[C-11]thymidine imaging of malignant brain tumors. Cancer Res. 1999, 59, 615-621.
106. Buck, A. K.; Hetzel, M.; Schirrmeister, H.; Halter, G.; Möller, P.; Kratochwil, C.; Wahl, A.; Glatting, G.; Mottaghy, F. M.; Mattfeldt, T.; Neumaier, B.; Reske, S. N. Clinical relevance of imaging proliferative activity in lung nodules. Eur. J. Nucl. Med. Mol. Imaging. 2005, 32, 525-533.
107. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur. J. Nucl. Med. Mol. Imaging. 2003, 30, 1407-1412.
108. Herrmann, K.; Ott, K.; Buck, A.; Souvatzoglou, M.; Wilhelm, D.; Watzlowik, P.; Dzewas, B.; Ulm, K.; Becker, K.; Wester, H.-J.; Siewert, J.-R.; Schwaiger, M.; Krause, B.-J. Detection of locally advanced gastric cancer with fluoro-18-thymidine and fluoro-18- fluorodeoxyglucose positron emission tomography. J. Nucl. Med. 2007, 48 (suppl 2), 27P.
109. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J. Nucl. Med. 2007, 48, 726-735.
110. 18F]FLT uptake after chemotherapy: an experimental study. Eur. J. Nucl. Med. Mol. Imaging. 2002, 29, 1462-1469.
111. Paproski, R. J.; Young, J. D.; Cass, C. E. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3 -deoxy-3 -fluorothymidine. Biochem. Pharm. 2010, 79, 587-595.
112. 18F]Fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with Positron Emission Tomography. Cancer Res. 2003, 63, 3791-3798.
113. 18F]FLT) positron emission tomography (PET). PLoS. ONE. 2008, 3, e3908.
114. Perumal, M.; Pillai, R. G.; Barthel, H.; Leyton, J.; Latigo, J. R.; Forster, M.; Mitchell, F.; Jackman, A. L.; Aboagye, E. O. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res. 2006, 66, 8558-8564.
115. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J. Nucl. Med. 2004, 45, 1754-1758.
116. 18F]fluorothymidine positron emission tomography: The effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005, 65, 4202-4210.
117. Sohn, H.-J.; Yang, Y.-J.; Ryu, J.-S.; Oh, S. J.; Im, K. C.; Moon, D. H.; Lee, D. H.; Suh, C.; Lee, J.-S.; Kim, S.-W. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin. Cancer Res. 2008, 14, 7423-7429.
118. 18F]fluorothymidine positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34, 1339-1347.
119. Chen, W.; Delaloye, S.; Silverman, D. H. S.; Geist, C.; Czernin, J.; Sayre, J.; Satyamurthy, N.; Pope, W.; Lai, A.; Phelps, M. E.; Cloughesy, T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F]fluorothymidine positron emission tomography: A pilot study. J. Clin. Oncol. 2007, 25, 4714-4721.
120. Pio, B.; Park, C.; Pietras, R.; Hsueh, W.-A.; Satyamurthy, N.; Pegram, M.; Czernin, J.; Phelps, M.; Silverman, D. Usefulness of 3 -[F-18]fluoro-3 -deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol. Imaging. Biol. 2006, 8, 36-42.
121. 18F]fluorothymidine- positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin. Cancer Res. 2007, 13, 3552-3558.
122. 18F-FLT uptake in patients with aggressive non-Hodgkin Lymphoma receiving R-CHOP treatment. J. Nucl. Med. 2011, 52, 690-696.
123. 18F]-3 Deoxy-3 - fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin. Cancer Res. 2011, 17, 7664-7672.
124. Campbell, D. O.; Yaghoubi, S. S.; Su, Y.; Lee, J. T.; Auerbach, M. S.; Herschman, H.; Satyamurthy, N.; Czernin, J.; Lavie, A.; Radu, C. G. Structure-guided engineering of human thymidine kinase 2 as a Positron Emission Tomography reporter gene for enhanced phosphorylation of non-natural thymidine analog reporter probe. J. Biol. Chem. 2012, 287, 446-454.
125. Tehrani, O. S.; Douglas, K. A.; Lawhorn-Crews, J. M.; Shields, A. F. Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2. Eur. J. Nucl. Med. Mol. Imaging. 2008, 35, 1480-1488.
126. 3H]BIMU-1, a 5- hydroxytryptamine3 receptor ligand in NG-108 cells, selectively labels sigma-2 binding sites in guinea pig hippocampus. J. Pharmacol. Exp. Ther. 1993, 267, 961-970.
127. Mach, R. H.; Vangveravong, S.; Huang, Y.; Yang, B.; Blair, J. B.; Wu, L. Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3 -yl phenylcarbamate analogs as sigma-2 receptor ligands. Med. Chem. Res. 2002, 11, 380-398.
128. Vangveravong, S.; Xu, J.; Zeng, C.; Mach, R. H. Synthesis of Nsubstituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg. Med. Chem. 2006, 14, 6988-6997.
129. Chu, W.; Xu, J.; Zhou, D.; Zhang, F.; Jones, L. A.; Wheeler, K. T.; Mach, R. H. New N-substituted 9-azabicyclo[3.3.1]nonan-3alphayl phenylcarbamate analogs as sigma-2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. Bioorg. Med. Chem. 2009, 17, 1222-1231.
130. Mach, R. H.; Yang, B.; Wu, L.; Kuhner, R. J.; Whirrett, B. R.; West, T. Synthesis and sigma receptor binding affinities of 8-azabicyclo[3.2.1]octan-3 -yl and 9-azabicyclo[3.3.1]nonan-3 -yl phenylcarbamates. Med. Chem. Res. 2001, 10, 339-355.
131. Mach, R. H.; Brown-Proctor, C.; Vangveravong, S.; Blair, J. B.; Buchheimer, N.; Bottoms, J.; Wheeler, K. T. Receptor-based radiotracers for Imaging the proliferative status of breast tumors. In Synthesis. and. Applications. of. Isotopically. Labelled. Compounds, Dean, D. C.; Filer, C. N.; McCarthy, K. E., Eds. John Wiley and Sons, Ltd.: Chichester, West Sussex, England, 2004; Vol. 8, pp 155-160.
132. Moltzen, E. K.; Perregaard, J.; Meier, E. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines. J. Med. Chem. 1995, 38, 2009-2017.
133. Ostenfeld, M. S.; Fehrenbacher, N.; Hoyer-Hansen, M.; Thomsen, C.; Farkas, T.; Jaattela, M. Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress. Cancer Res. 2005, 65, 8975-8983.
134. 18F-labelled 2 receptor ligands for positron emission tomography (PET). J. Labelled. Compd. Radiopharm. 2005, 48, 31-43.
135. Mach, R. H.; Huang, Y.; Freeman, R. A.; Wu, L.; Vangveravong, S.; Luedtke, R. R. Conformationally-flexible benzamide analogues as dopamine D3 and sigma-2 receptor ligands. Bioorg. Med. Chem. Lett. 2004, 14, 195-202.
136. Chu, W.; Tu, Z.; McElveen, E.; Xu, J.; Taylor, M.; Luedtke, R. R.; Mach, R. H. Synthesis and in vitro binding of N-phenyl piperazine analogs as potential dopamine D3 receptor ligands. Bioorg. Med. Chem. 2005, 13, 77-87.
137. Tu, Z.; Li, S.; Cui, J.; Xu, J.; Taylor, M.; Ho, D.; Luedtke, R. R.; Mach, R. H. Synthesis and pharmacological evaluation of fluorine- containing D3 dopamine receptor ligands. J. Med. Chem. 2011, 54, 1555-1564.
138. Hou, C.; Tu, Z.; Mach, R.; Kung, H. F.; Kung, M.-P. Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. Nucl. Med. Biol. 2006, 33, 203-209.
139. 3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin- 2(1H)-yl)butyl]-2-methoxy-5 -methylbenzamide: A novel sigma-2 receptor probe. Eur. J. Pharmacol. 2005, 525, 8-17.
140. Tu, Z.; Dence, C. S.; Ponde, D. E.; Jones, L.; Wheeler, K. T.; Welch, M. J.; Mach, R. H. Carbon-11 labeled sigma-2 receptor ligands for imaging breast Cancer Nucl. Med. Biol. 2005, 32, 423-430.
141. Tu, Z.; Xu, J.; Jones, L. A.; Li, S.; Dumstorff, C.; Vangveravong, S.; Chen, D. L.; Wheeler, K. T.; Welch, M. J.; Mach, R. H. Fluorine-18-labeled benzamide analogues for imaging the sigma-2 receptor status of solid tumors with positron emission tomography. J. Med. Chem. 2007, 50, 3194-3204.
142. 18F-ISO-1. J. Nucl. Med. 2013, 54, 350-357.